Colinz Laboratories open offer: ₹54 price, dates in 2026

What has been announced

Colinz Laboratories Limited has received a public announcement for a mandatory open offer after a change-of-control transaction was agreed with the existing promoter. The acquirers are Annjana Dugar, Likhitta Dugar and Antariksh Dugar, along with Padam Dugar as the Person Acting in Concert (PAC). The open offer is for up to 6,54,966 fully paid-up equity shares, which represents 26% of the company’s voting share capital. The offer price is ₹54 per share, taking the total cash consideration to about ₹3.5368 crore.

Acquirers, PAC and the trigger event

The open offer has been triggered following a Share Purchase Agreement (SPA) dated June 18, 2026. Under this SPA, the acquirers agreed to buy shares from Vijaya Mani, described as the existing promoter and selling shareholder. The transaction is being carried out under the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011, which require an open offer when certain acquisition thresholds are crossed. The announcement also notes that the transaction is expected to result in a change of control.

Details of the share purchase agreement

The SPA involves the purchase of 8,70,500 equity shares, which constitutes 34.56% of Colinz Laboratories’ voting share capital. The negotiated SPA price is ₹50 per share, implying an underlying consideration of about ₹4.3525 crore. After the completion of this purchase, the acquirers’ shareholding is stated to rise to 37.01%. This post-acquisition holding level is what triggers the mandatory open offer for an additional 26%.

Open offer size and pricing mechanics

The open offer is for 6,54,966 shares, and it is priced at ₹54 per share. The announcement states that the offer price has been determined in accordance with SEBI regulations, considering the highest negotiated price under the SPA and the volume-weighted average market price. The offer is payable in cash. It is also explicitly stated that the offer is not conditional on a minimum level of acceptance and that it is not a competitive offer.

Funding and intermediaries

To fund the open offer, the acquirers have opened an escrow cash account with ICICI Bank and deposited ₹89 lakh (₹0.89 crore). The announcement notes that this deposit is more than 25% of the total offer consideration. Saffron Capital Advisors Private Limited has been appointed as the Manager to the Open Offer. Bigshare Services Private Limited has been named as the Registrar to the offer.

Key dates and how shareholders can tender

The tendering period is scheduled to open on August 11, 2026, and close on August 24, 2026. The last date for payment of consideration to shareholders is September 8, 2026. Public shareholders holding shares in dematerialised as well as physical form are eligible to participate. Tendering is to be done through the BSE acquisition window, as per the disclosed process.

Snapshot of the disclosed numbers

Market context: price, trading framework and disclosures

Colinz Laboratories’ share price was cited at ₹71.96 as of June 24, 2026 (11:41 IST). The stock is stated to have a market lot size of 1, and the company is noted as being under the “No framework” category in the provided data. Separately, Colinz Laboratories has informed the BSE that it is exempt from submitting Related Party Transaction disclosures for the quarter ended June 30, 2026, citing an exemption under SEBI LODR Regulation 15(2)(a). The disclosure notes this exemption also relieves the company from compliance with provisions in Regulations 17 to 27 and specific clauses of Regulation 46 for the stated period.

Other corporate update mentioned alongside the open offer

The provided information also states that Colinz Laboratories completed the sale of its factory undertaking in Nashik for ₹4 crore. It says the company received the final tranche on June 18, 2026. The buyer is identified as Hilsun Foods And Drugs Private Limited, and the transaction is described as executed at arm’s length and not a related party transaction.

What the acquirers have said about delisting

The acquirers have stated that they do not intend to delist the equity shares of the company. This matters for public shareholders because delisting intent can change how investors assess post-offer outcomes. The announcement also clarifies the open offer is not competitive and does not depend on achieving a minimum acceptance threshold.

Timeline of key events

Why this matters for investors

This transaction combines a negotiated promoter stake purchase with a mandatory open offer under the SEBI Takeover Regulations, 2011. For public shareholders, the practical decision point is whether to tender shares at ₹54 during the offer window, given the market price cited at ₹71.96 on June 24, 2026. The disclosures also outline process safeguards such as escrow funding and the appointment of a manager and registrar. Separately, the company’s regulatory exemptions and the Nashik undertaking sale provide additional corporate context that investors may track alongside the change-of-control process.

Conclusion

Colinz Laboratories is set for a change of control following the June 18, 2026 SPA, with the Dugar family acquirers and PAC launching a 26% open offer at ₹54 per share. The offer opens on August 11, 2026 and closes on August 24, 2026, with payment due by September 8, 2026. The next confirmed milestones are the tendering window and subsequent settlement as per the published schedule.